| (210) | Number of the EPO application | 16805576 |
| (220) | Filing date of the EPO application | 2016.11.03 |
| (80) | EPO patent specification publication (B) | EPB nr. 16/2023, 2023.04.19 |
| (110) | EPO patent number | 3370775 |
| (21) | Number of the application | e 2018 0888 |
| (71) | Name(s) of applicant(s), code of the country | Genentech, Inc., US;
Board of Regents, The University of Texas System, US; |
| (72) | Name(s) of inventor(s), code of the country | MERCHANT Mark, US;
SAMPATH Deepak, US;
KONOPLEVA Marina Yurievna, US;
HAN Lina, US; |
| (73) | Name(s) of owner(s), code of the country | GENENTECH Inc., US;
Board of Regents, The University of Texas System, US; |
| (54) | Title of the invention | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/4523 (2006.01.01); A61K 31/496 (2006.01.01); A61P 35/00 (2006.01.01); A61P 35/02 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2018.10.31 |
| (30) | Priority | 201562250231 P, 2015.11.03, US; 201562263082 P, 2015.12.04, US |
| (86) | International application | PCT/US2016/060271, 2016.11.03 |
| (87) | International publication | WO 2017/079399, 2017.05.11 |